98 related articles for article (PubMed ID: 29277764)
1. Distribution of Curcumin and THC in Peripheral Blood Mononuclear Cells Isolated from Healthy Individuals and Patients with Chronic Lymphocytic Leukemia.
Bolger GT; Licollari A; Tan A; Greil R; Pleyer L; Vcelar B; Majeed M; Sordillo P
Anticancer Res; 2018 Jan; 38(1):121-130. PubMed ID: 29277764
[No Abstract] [Full Text] [Related]
2. Distribution and Metabolism of Lipocurc™ (Liposomal Curcumin) in Dog and Human Blood Cells: Species Selectivity and Pharmacokinetic Relevance.
Bolger GT; Licollari A; Tan A; Greil R; Vcelar B; Majeed M; Helson L
Anticancer Res; 2017 Jul; 37(7):3483-3492. PubMed ID: 28668837
[TBL] [Abstract][Full Text] [Related]
3. Intense Uptake of Liposomal Curcumin by Multiple Myeloma Cell Lines: Comparison to Normal Lymphocytes, Red Blood Cells and Chronic Lymphocytic Leukemia Cells.
Bolger GT; Licollari A; Bagshaw R; Tan A; Greil R; Vcelar B; Majeed M; Sordillo P
Anticancer Res; 2019 Mar; 39(3):1161-1168. PubMed ID: 30842145
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of liposomal curcumin (Lipocurc™) infusion: effect of co-medication in cancer patients and comparison with healthy individuals.
Bolger GT; Licollari A; Tan A; Greil R; Vcelar B; Greil-Ressler S; Weiss L; Schönlieb C; Magnes T; Radl B; Majeed M; Sordillo PP
Cancer Chemother Pharmacol; 2019 Feb; 83(2):265-275. PubMed ID: 30430227
[TBL] [Abstract][Full Text] [Related]
5. Infusion pharmacokinetics of Lipocurc™ (liposomal curcumin) and its metabolite tetrahydrocurcumin in Beagle dogs.
Helson L; Bolger G; Majeed M; Vcelar B; Pucaj K; Matabudul D
Anticancer Res; 2012 Oct; 32(10):4365-70. PubMed ID: 23060560
[TBL] [Abstract][Full Text] [Related]
6. Tissue distribution of (Lipocurc™) liposomal curcumin and tetrahydrocurcumin following two- and eight-hour infusions in Beagle dogs.
Matabudul D; Pucaj K; Bolger G; Vcelar B; Majeed M; Helson L
Anticancer Res; 2012 Oct; 32(10):4359-64. PubMed ID: 23060559
[TBL] [Abstract][Full Text] [Related]
7. Detection of chromosomal abnormalities in chronic lymphocytic leukemia increased by interphase fluorescence in situ hybridization in tetradecanoylphorbol acetate-stimulated peripheral blood cells.
Sánchez J; Aventín A
Cancer Genet Cytogenet; 2007 May; 175(1):57-60. PubMed ID: 17498559
[TBL] [Abstract][Full Text] [Related]
8. Preclinical assessment of curcumin as a potential therapy for B-CLL.
Everett PC; Meyers JA; Makkinje A; Rabbi M; Lerner A
Am J Hematol; 2007 Jan; 82(1):23-30. PubMed ID: 16947318
[TBL] [Abstract][Full Text] [Related]
9. In Vitro Study of a Liposomal Curcumin Formulation (Lipocurc™): Toxicity and Biological Activity in Synovial Fibroblasts and Macrophages.
Kloesch B; Gober L; Loebsch S; Vcelar B; Helson L; Steiner G
In Vivo; 2016; 30(4):413-9. PubMed ID: 27381602
[TBL] [Abstract][Full Text] [Related]
10. The use of tetradecanoylphorbol acetate-stimulated peripheral blood cells enhances the prognostic value of interphase fluorescence in situ hybridization in patients with chronic lymphocytic leukemia.
Delgado J; Aventin A; Briones J; Sanchez J; Nomdedeu J; Sierra J
Genes Chromosomes Cancer; 2010 Apr; 49(4):327-32. PubMed ID: 20033916
[TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability and pharmacokinetics of liposomal curcumin in healthy humans.
Storka A; Vcelar B; Klickovic U; Gouya G; Weisshaar S; Aschauer S; Bolger G; Helson L; Wolzt M
Int J Clin Pharmacol Ther; 2015 Jan; 53(1):54-65. PubMed ID: 25500488
[TBL] [Abstract][Full Text] [Related]
12. Modulation of IL-4 level by fludarabine and its relation to apoptosis in chronic B-cell lymphocytic leukemia.
Shamaa LA; Hussein Ael-S; Balbaa OA; Farahat NM; Ali MA
Egypt J Immunol; 2008; 15(1):181-92. PubMed ID: 20306682
[TBL] [Abstract][Full Text] [Related]
13. Glutamate dehydrogenase activity in lymphocytes of B-cell chronic lymphocytic leukaemia patients.
Pajic T; Cernelc P; Sesek Briski A; Lejko-Zupanc T; Malesic I
Clin Biochem; 2009 Nov; 42(16-17):1677-84. PubMed ID: 19683518
[TBL] [Abstract][Full Text] [Related]
14. Relative Expression of BATF and CD112 in PBMC of Patients with Chronic Lymphocytic Leukemia.
Najafi A; Sabaghi M; Asgarian-Omran H; Valadan R; Shekarriz R; Zaboli E; Janbabai G; Tehrani M
Asian Pac J Cancer Prev; 2023 Jun; 24(6):2171-2176. PubMed ID: 37378949
[TBL] [Abstract][Full Text] [Related]
15. Carboxymethylcellulose-tetrahydrocurcumin conjugates for colon-specific delivery of a novel anti-cancer agent, 4-amino tetrahydrocurcumin.
Plyduang T; Lomlim L; Yuenyongsawad S; Wiwattanapatapee R
Eur J Pharm Biopharm; 2014 Oct; 88(2):351-60. PubMed ID: 24859389
[TBL] [Abstract][Full Text] [Related]
16. Total expression of HLA-G and TLR-9 in chronic lymphocytic leukemia patients.
Własiuk P; Tomczak W; Zając M; Dmoszyńska A; Giannopoulos K
Hum Immunol; 2013 Dec; 74(12):1592-7. PubMed ID: 23994589
[TBL] [Abstract][Full Text] [Related]
17. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
[TBL] [Abstract][Full Text] [Related]
18. Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells.
Secchiero P; Tiribelli M; Barbarotto E; Celeghini C; Michelutti A; Masolini P; Fanin R; Zauli G
J Cell Physiol; 2005 Nov; 205(2):246-52. PubMed ID: 15887227
[TBL] [Abstract][Full Text] [Related]
19. Tetrahydrocurcumin-loaded vaginal nanomicrobicide for prophylaxis of HIV/AIDS: in silico study, formulation development, and in vitro evaluation.
Mirani A; Kundaikar H; Velhal S; Patel V; Bandivdekar A; Degani M; Patravale V
Drug Deliv Transl Res; 2019 Aug; 9(4):828-847. PubMed ID: 30900133
[TBL] [Abstract][Full Text] [Related]
20. Synergistic immunosuppressive effects of the mTOR inhibitor sirolimus and the phytochemical curcumin.
Deters M; Hütten H; Kaever V
Phytomedicine; 2013 Jan; 20(2):120-3. PubMed ID: 23079231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
